tkis gefitinib (AstraZeneca ltd)
90
Structured Review
AstraZeneca ltd
tkis gefitinib
Tkis Gefitinib, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tkis/pmc03334713-72-0-2?v=AstraZeneca+ltd
Average 90 stars, based on 1 article reviews
Tkis Gefitinib, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/tkis/pmc03334713-72-0-2?v=AstraZeneca+ltd
Average 90 stars, based on 1 article reviews
tkis gefitinib - by Bioz Stars,
2026-08
90/100 stars
Images
1) Product Images from "Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab"
Article Title: Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
Journal: BMC Medicine
doi: 10.1186/1741-7015-10-28
Figure Legend Snippet: Effect of TKI treatment on cell growth inhibition and apoptosis induction . Effect of TKIs gefitinib, erlotinib, and afatinib and cetuximab on the growth (A) and caspase3/7 activity (B) of HCC827, H292, H358, H1650, and H1975 cells after 72-h incubation. Independent experiments were repeated six times and one representative result is shown. Points, mean value of six identical wells of a single representative experiments; bars, SD (n = 6).
Techniques Used: Inhibition, Activity Assay, Incubation
Figure Legend Snippet: Effect of adding an EGFR siRNA to gefitinib on cell growth inhibition . Lung cancer cells were treated with gefitinib 24 h before the EGFR siRNA transfection. After transfecting the siRNA, the cells were incubated for another 48 h, after which cellular growth was assessed by the MTS assay. (A) shows the combination effect of gefitinib and siRNA. * P < 0.05 and ** P < 0.01 compared to controls with only siRNA transfection. "black triangle" P < 0.05 and "double black triangles" P < 0.01 compared to agents plus control siRNA. Median-effect plot (B) , dose-effect curve (C) , Fa-CI plot (D) , and normalized isobologram (E) were computationally generated by Biosoft CalcuSyn program with EGFR siRNA and combined to gefitinib in H358 cells. Similar additive effect was found in all the combinations in all the five cell lines (data not shown).
Techniques Used: Inhibition, Transfection, Incubation, MTS Assay, Control, Generated
Figure Legend Snippet: Enhancement of apoptosis induction by the combination of EGFR siRNA plus gefitinib or erlotinib . Lung cancer cells were treated with different drugs 24 h before the EGFR siRNA transfection. Forty-eight hours post transfection, the cell cultures were assayed for caspase-3/7 activity. ( A : gefitinib; B : erlotinib). * P < 0.05 and ** P < 0.01 compared to controls with siRNA transfection alone. "black triangle" P < 0.05 and "double black triangles" P < 0.01 compared to agents plus control siRNA.
Techniques Used: Transfection, Activity Assay, Control